Gelatin thrombin matrix sealant (Floseal).
Flowable agents such as Floseal® (F) are often reserved as adjuncts to non-flowable agents (i.e., Gelatin sponges [G] and thrombin [T]) when bleeding is not sufficiently controlled. Based on their perceived positive impact it is postulated that flowable agents alone may result in better clinical and resource utilization outcomes.
The use of flowable hemostatic agents alone may result in better clinical and possibly economic outcomes in spine surgery 1).
Association with thrombin and thromboembolic events in patients undergoing tumor resection has been suggested. A study evaluates the relationship between flowable hemostatic matrix and deep vein thrombosis in a large cohort of patients treated for brain tumor removal. The authors conducted a retrospective, multicenter, clinical review of all craniotomies for tumor removal performed between 2013 and 2014. Patients were classified in three groups: group I (flowable gelatin hemostatic matrix with thrombin), group II (gelatin hemostatic without thrombin), and group III (classical hemostatic). A total of 932 patients were selected: tumor pathology included 441 gliomas, 296 meningiomas, and 195 metastases. Thromboembolic events were identified in 4.7% of patients in which gelatin matrix with thrombin was applied, in 8.4% of patients with gelatin matrix without thrombin, and in 3.6% of cases with classical methods of hemostasis. Patients with venous thromboembolism had an increased proportion of high-grade gliomas (7.2%). Patients receiving a greater dose than 10 ml gelatin hemostatic had a higher rate of thromboembolic events. Intracranial hematoma requiring reintervention occurred in 19 cases: 4.5% of cases of group III, while reoperation was performed in 1.3 and 1.6% of patients in which gelatin matrix with or without thrombin was applied. Gelatin matrix hemostat is an efficacious tool for neurosurgeons in cases of difficult intraoperative bleeding during cranial tumor surgery. This study may help to identify those patients at high risk for developing thromboembolism and to treat them accordingly 6).
Application of FLOSEAL Hemostatic Matrix in a Frontal MAV procedure